Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1996 1
1997 1
2005 2
2006 1
2007 3
2008 3
2009 4
2010 3
2011 3
2012 3
2013 2
2015 3
2017 1
2018 2
2019 2
2020 1
2021 3
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Development and deployment of COVID-19 vaccines for those most vulnerable.
Koff WC, Schenkelberg T, Williams T, Baric RS, McDermott A, Cameron CM, Cameron MJ, Friemann MB, Neumann G, Kawaoka Y, Kelvin AA, Ross TM, Schultz-Cherry S, Mastro TD, Priddy FH, Moore KA, Ostrowsky JT, Osterholm MT, Goudsmit J. Koff WC, et al. Among authors: priddy fh. Sci Transl Med. 2021 Feb 3;13(579):eabd1525. doi: 10.1126/scitranslmed.abd1525. Sci Transl Med. 2021. PMID: 33536277 Review.
AIDS vaccines and preexposure prophylaxis: is synergy possible?
Excler JL, Rida W, Priddy F, Gilmour J, McDermott AB, Kamali A, Anzala O, Mutua G, Sanders EJ, Koff W, Berkley S, Fast P. Excler JL, et al. Among authors: priddy f. AIDS Res Hum Retroviruses. 2011 Jun;27(6):669-80. doi: 10.1089/AID.2010.0206. Epub 2010 Dec 16. AIDS Res Hum Retroviruses. 2011. PMID: 21043994 Free PMC article. Review.
Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults.
Priddy FH, Williams M, Carson S, Lavender B, Mathieson J, Frampton C, Moreland NJ, McGregor R, Williams G, Brewerton M, Gell K, Ussher J, Le Gros G. Priddy FH, et al. Vaccine. 2022 Aug 12;40(34):5050-5059. doi: 10.1016/j.vaccine.2022.07.009. Epub 2022 Jul 12. Vaccine. 2022. PMID: 35868948 Free PMC article.
Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
Stephenson KE, Julg B, Tan CS, Zash R, Walsh SR, Rolle CP, Monczor AN, Lupo S, Gelderblom HC, Ansel JL, Kanjilal DG, Maxfield LF, Nkolola J, Borducchi EN, Abbink P, Liu J, Peter L, Chandrashekar A, Nityanandam R, Lin Z, Setaro A, Sapiente J, Chen Z, Sunner L, Cassidy T, Bennett C, Sato A, Mayer B, Perelson AS, deCamp A, Priddy FH, Wagh K, Giorgi EE, Yates NL, Arduino RC, DeJesus E, Tomaras GD, Seaman MS, Korber B, Barouch DH. Stephenson KE, et al. Among authors: priddy fh. Nat Med. 2021 Oct;27(10):1718-1724. doi: 10.1038/s41591-021-01509-0. Epub 2021 Oct 7. Nat Med. 2021. PMID: 34621054 Free PMC article. Clinical Trial.
Measles immunity gap among reproductive-age women participating in a simulated HIV vaccine efficacy trial in Zambia.
Malama K, Tichacek A, Kelly H, Parker R, Inambao M, Sharkey T, Wall KM, Kilembe W, Price MA, Fast P, Priddy F, Allen S. Malama K, et al. Among authors: priddy f. Hum Vaccin Immunother. 2022 Nov 30;18(5):2066426. doi: 10.1080/21645515.2022.2066426. Epub 2022 Apr 21. Hum Vaccin Immunother. 2022. PMID: 35446726 Free PMC article. Clinical Trial.
Cohort Profile: IAVI's HIV epidemiology and early infection cohort studies in Africa to support vaccine discovery.
Price MA, Kilembe W, Ruzagira E, Karita E, Inambao M, Sanders EJ, Anzala O, Allen S, Edward VA, Kaleebu P, Fast PE, Rida W, Kamali A, Hunter E, Tang J, Lakhi S, Mutua G, Bekker LG, Abu-Baker G, Tichacek A, Chetty P, Latka MH, Maenetje P, Makkan H, Hare J, Kibengo F, Priddy F, Landais E, Chinyenze K, Gilmour J. Price MA, et al. Among authors: priddy f. Int J Epidemiol. 2021 Mar 3;50(1):29-30. doi: 10.1093/ije/dyaa100. Int J Epidemiol. 2021. PMID: 32879950 Free PMC article. No abstract available.
Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.
Lavender B, Hooker C, Frampton C, Williams M, Carson S, Paterson A, McGregor R, Moreland NJ, Gell K, Priddy FH, Wiig K, Le Gros G, Ussher JE, Brewerton M. Lavender B, et al. Among authors: priddy fh. Vaccine. 2023 Aug 31;41(38):5535-5544. doi: 10.1016/j.vaccine.2023.07.051. Epub 2023 Jul 27. Vaccine. 2023. PMID: 37516574 Free article.
46 results